Unknown

Dataset Information

0

Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery.


ABSTRACT: We report detailed susceptibility profiling of asexual blood stages of the malaria parasite Plasmodium falciparum to clinical and experimental antimalarials, combined with metabolomic fingerprinting. Results revealed a variety of stage-specific and metabolic profiles that differentiated the modes of action of clinical antimalarials including chloroquine, piperaquine, lumefantrine, and mefloquine, and identified late trophozoite-specific peak activity and stage-specific biphasic dose-responses for the mitochondrial inhibitors DSM265 and atovaquone. We also identified experimental antimalarials hitting previously unexplored druggable pathways as reflected by their unique stage specificity and/or metabolic profiles. These included several ring-active compounds, ones affecting hemoglobin catabolism through distinct pathways, and mitochondrial inhibitors with lower propensities for resistance than either DSM265 or atovaquone. This approach, also applicable to other microbes that undergo multiple differentiation steps, provides an effective tool to prioritize compounds for further development within the context of combination therapies.

SUBMITTER: Murithi JM 

PROVIDER: S-EPMC7031696 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery.

Murithi James M JM   Owen Edward S ES   Istvan Eva S ES   Lee Marcus C S MCS   Ottilie Sabine S   Chibale Kelly K   Goldberg Daniel E DE   Winzeler Elizabeth A EA   Llinás Manuel M   Fidock David A DA   Vanaerschot Manu M  

Cell chemical biology 20191205 2


We report detailed susceptibility profiling of asexual blood stages of the malaria parasite Plasmodium falciparum to clinical and experimental antimalarials, combined with metabolomic fingerprinting. Results revealed a variety of stage-specific and metabolic profiles that differentiated the modes of action of clinical antimalarials including chloroquine, piperaquine, lumefantrine, and mefloquine, and identified late trophozoite-specific peak activity and stage-specific biphasic dose-responses fo  ...[more]

Similar Datasets

2019-07-09 | ST001232 | MetabolomicsWorkbench
| S-EPMC4635350 | biostudies-literature
| S-EPMC9163384 | biostudies-literature
| S-EPMC5075069 | biostudies-literature
| S-EPMC7179595 | biostudies-literature
2011-10-31 | E-GEOD-32485 | biostudies-arrayexpress
| S-EPMC4002183 | biostudies-other
| S-EPMC8608365 | biostudies-literature
| S-EPMC6072474 | biostudies-literature
2011-10-31 | GSE32485 | GEO